Sagimet Biosciences Inc. Series A Common Stock (SGMT)
Sagimet Biosciences Inc. Series A (SGMT) is a biotechnology company focused on developing innovative therapies for metabolic and fibrotic diseases. The company specializes in targeting liver and metabolic disorders through novel small molecule drugs, aiming to address unmet medical needs in these areas.
Company News
Sagimet Biosciences reported positive Phase 3 clinical trial results for denifanstat, a novel oral medication for treating moderate to severe acne, with significant improvements in lesion reduction and treatment success rates.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Stifel cut the price target for Spire Global, Inc. (NYSE:SPIR) from $24 to $20. Stifel analyst Erik Rasmussen maintained a Buy rating. Spire Global shares fell 6.8% to close at $11.34 on Wednesday. See how other analysts view this stock. Oppenheimer boosted the price target for Analog Devices, Inc. (NASDAQ:ADI) from $215 to $245. Oppenheimer analyst Rick Schafer maintained an Outperform rating. Analog Devices shares rose 1.8% to close at $215.75 on Wednesday. See how other analysts view this stock. Goldman Sachs cut Sagimet Biosciences Inc.. (NASDAQ:SGMT) price target from $27 to $23. Goldman Sachs analyst Andrea Tan maintained a Buy rating. Sagimet Biosciences shares rose 5.5% to close ...Full story available on Benzinga.com
This article discusses the upcoming events in the financial world, including the Federal Reserve meeting, corporate earnings, IPOs, and investor events.